With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims
This article was originally published in The Tan Sheet
Executive Summary
In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product
You may also be interested in...
US-Canada Pilot Could Help FDA's OTC Monograph Update Fly
HHS' latest semi-annual regulatory agenda lists a US-Canada Regulatory Cooperation Council pilot program as the source of a proposed rule to add the common cold indication for monograph OTC antihistamine ingredients that FDA plans to introduce in March 2016.
US-Canada Pilot Could Help FDA's OTC Monograph Update Fly
HHS' latest semi-annual regulatory agenda lists a US-Canada Regulatory Cooperation Council pilot program as the source of a proposed rule to add the common cold indication for monograph OTC antihistamine ingredients that FDA plans to introduce in March 2016.
E-Cigarette ‘Deeming’ Rule In OMB Review As Health Groups Urge Claim Enforcement
FDA’s proposed final rule to deem e-cigarettes and other novel products, cigars and pipe tobacco subject to its tobacco oversight is under OMB review. The American Cancer Society and other medical groups, meanwhile, urge immediate action against e-cigarette marketers making smoking cessation claims.